Uncategorized

Clinical Manifestations of Infection with Poliomyelitis Virus | Spike Protein-independent Attenuation of SARS-CoV-2 Omicron Variant in Laboratory Mice | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study | Distinguishing features of Long COVID identified through immune profiling | Unexplained post-acute infection syndromes | Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge | Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children

Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination — PCORnet, United States, January 2021–January 2022 | Clinical characteristics, activity levels and mental health problems in children with long coronavirus disease: a survey of 510 children | Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children | Protection by a Fourth Dose of BNT162b2 against Omicron in Israel | Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

Effect of Early Treatment with Ivermectin among Patients with COVID-19 | Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19A Randomized Clinical Trial | Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19 | Prone positioning of patients with moderate hypoxaemia due to covid-19: multicenter pragmatic randomized trial (COVID-PRONE) | U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals

COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status — COVID-NET, 14 States, July 2021–January 2022 | Intrinsic Severity of SARS-CoV-2 Omicron BA.2 in Uninfected, Unvaccinated Children: A Population-Based, Case-Control Study on Hospital Complications | SARS-CoV-2 Placentitis and Intraparenchymal Thrombohematomas Among COVID-19 Infections in Pregnancy | De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report

Children and COVID19: State Level Data Report | Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022 | Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 | High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron | Comparison of Seroconversion in Children and Adults With Mild COVID-19

SARS-CoV-2 is associated with changes in brain structure | New Onset Dementia Among Survivors of Pneumonia Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Whole genome sequencing reveals host factors underlying critical Covid-19 | Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality | Pfizer Initiated a Phase 2/3 Study of their Novel COVID-19 Oral Treatment in Pediatric Participants | Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID | Development and validation of SCOPE score: a clinical score to predict progression of COVID-19 pneumonia to severe respiratory failure | Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant | Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network